Hengrui Pharma(SH:600276) Zhi Tong Cai Jing·2025-07-28 08:52Market Overview - The Hong Kong stock market experienced mixed performance with the Hang Seng Index rising by 0.68% to close at 25,562.13 points, while the Hang Seng Technology Index fell by 0.24% [1] - The total trading volume for the day was 250.3 billion HKD [1] Blue-Chip Stocks Performance - China National Pharmaceutical (01177) led blue-chip stocks with a 7.09% increase, closing at 7.25 HKD, contributing 7.74 points to the Hang Seng Index [2] - Other notable performers included Hansoh Pharmaceutical (03692) up 5.83% and CSPC Pharmaceutical (01093) up 5.45% [2] Sector Highlights - The innovative drug sector saw significant gains, with Hengrui Medicine (01276) surging by 24.54% after announcing a collaboration with GSK worth up to 12.5 billion USD [3][4] - Insurance stocks also performed well, with AIA Group (01299) rising by 4.96% following a reduction in the preset interest rates for life insurance products [4][5] Regulatory Developments - The Hong Kong Stablecoin Regulation will take effect on August 1, 2025, with initial licenses to be granted to a limited number of applicants [6] - The regulation aims to enhance compliance and support the development of the stablecoin industry [6] Commodity Market Impact - The commodity futures market saw significant declines, with major products like coking coal and glass dropping by 11% and 9% respectively, attributed to regulatory limits on trading [7] Notable Stock Movements - China Tobacco Hong Kong (06055) rose by 13.32% after the release of a draft regulation on the domestic duty-free tobacco market [8] - CATL (300750) reached a new high, increasing by 6.24%, with expectations of strong revenue growth in the upcoming earnings report [9] - China Duty Free Group (601888) fell by 5.55% after reporting a 9.96% decline in total revenue for the first half of 2025 [10]